Differential distribution of β-endorphin and enkephalins in rat and bovine brain

Intrathecal methadone: a dose-response study and comparison with intrathecal morphine 0.5 mg

The analgesic and adverse effects of intrathecal methadone 5 mg, 10 mg and 20 mg were assessed and compared with intrathecal morphine 0.5 mg. The study was conducted on 38 patients who underwent total knee or hip replacement surgery. The intrathecal opioid was administered at the end of surgery and assessments began 1 h thereafter and continued for 24 h. Pain measurements, supplementary analgesia requirements, and adverse effects were recorded. Intrathecal morphine 0.5 mg provided effective and prolonged analgesia. Intrathecal methadone 5 mg, 10 mg, and 20 mg produced good analgesia of 4 h duration. Thereafter the median pain scores with intrathecal methadone were consistently higher (worse) than those with intrathecal morphine (P less than 0.05). The time to the onset of discomfort severe enough to require supplemental morphine was longer after intrathecal morphine than following methadone (15 h with morphine 0.5 mg; 6.25 h, 6.5 h and 6 h with methadone 5 mg, 10 mg, and 20 mg respectively: P less than 0.05). Central nervous system depression manifesting as respiratory depression, hypotension, and excessive drowsiness occurred in 3 of 8 patients injected with methadone 20 mg intrathecally. Generalized pruritus, nausea, vomiting, and urinary retention were common and equally distributed among the treatment groups. We conclude that both intrathecal morphine 0.5 mg and methadone 5, 10, and 20 mg provide excellent analgesia but that morphine has a more prolonged effect. Methadone 20 mg produced unacceptable side effects. Clinical evidence for rostral spread of methadone within the CSF, as indicated by facial itching and excessive drowsiness, was less apparent with 5 mg than with 10 and 20 mg. Various explanations for the observed differences between the drugs are discussed.

Effects of enkephalins and the analogue FK-33824 on mean arterial pressure and heart rate in conscious sheep

Experiments were designed to evaluate the central and systemic effects by enkephalins and the enkephalin analogue FK-33824 on mean arterial pressure (MAP) and heart rate (HR) in conscious sheep. Intracerebroventricular infusion of FK-33824 increased both MAP and HR in a dose-dependent manner in normal sheep. The increases in MAP and HR were attenuated by naloxone administered centrally, but not systemically. Intracerebroventricular infusion of met-enkephalin, leu-enkephalin and naloxone failed to change both MAP and HR significantly. However, intravenous infusion of met-enkephalin, leu-enkephalin and FK-33824 resulted in bradycardia. Haemorrhage alone decreased both MAP and HR. Intracerebroventricular infusion of FK-33824 blunted the reduction in MAP in response to haemorrhage. The increases in MAP and HR following FK-33824 were also accompanied by elevated levels of plasma renin concentration. It is suggested that the tachycardia and pressor effect produced by the intracerebroventricular administration of FK-33824 in normal conscious sheep may result from a combined action of both neural and chemical pathways which are involved in cardiovascular control, and are mediated via the mu-opioid receptors. Opioids may have opposite effects on cardiovascular control depending on the route of administration.

Regional processing of the N- and C-terminal domains of proopiomelanocortin in monkey pituitary and brain

The total content and extent of processing of the gamma 3MSH and beta-endorphin-containing N- and C-terminal domains of proopiomelanocortin were determined in the anterior and intermediate lobes of the pituitaries and in 11 regions of the brains of three Rhesus monkeys. Most immunoreactive gamma 3MSH and beta-endorphin was located in the pituitary lobes, although significant amounts were also found in several brain regions. Sephadex column chromatography revealed that gamma 3MSH immunoreactivity was found primarily as 4K and 9K forms; no gamma 1MSH was detected. beta-Endorphin immunoreactivity was found as beta-endorphin, beta-lipotropin, and as a 5K form which may represent beta-endorphin extended N-terminally by part or all of beta-MSH. In the anterior lobe of the pituitary, the predominant products were 9K gamma 3MSH and beta-lipotropin; in the intermediate lobe, more processed forms (4K gamma 3MSH, beta-endorphin and 5K beta-endorphin) appeared to be preferentially stored. The pattern of processing in various brain regions was similar to that of the intermediate lobe of the pituitary.

The enkephalin response in human tooth pulp to orthodontic force

Public perception is that dentistry and pain go hand in hand; thus, pain and pain control are important considerations to the profession. Recent studies have attempted to discover the precise metabolic events involved in neural transmission of nociceptive information. One focus has been the study of peptidergic pathways, which purportedly inhibit the firing of pain-conducting fibers. The research described in this article defined the existence of one enkephalin, methionine enkephalin (ME), in an extract of human tooth pulp tissue and the effect of orthodontic force on that ME concentration. One set of patients who had premolars extracted for orthodontic purposes served as controls. Another set, also diagnosed for premolar extractions, had a coil spring attached between the left and right maxillary premolars to supply an orthodontic force for a period of time prior to extraction. High-performance liquid chromatography, radioimmunoassay, radioreceptor assay, and mass spectrometry were used in a series of experiments to isolate, identify, and quantify ME in the pulp tissues. Principal results were as follows: for the first time ME was detected in human tooth pulp, orthodontic force caused a significant decrease in ME concentrations in the group of experimental teeth compared with controls, and ME levels of the first spring-attached tooth that was removed from each patient had a statistically significant inverse log-linear relationship to the amount of applied force. These data indicate that orthodontic force mobilizes at least one neuropeptidergic pathway in the human tooth pulp.

Central nervous system actions of beta-endorphin on gastric acid secretion

We assessed the central nervous system (CNS) actions of beta-endorphin on gastric acid secretion in awake dogs. Synthetic beta-endorphin (0.2-2.0 nmol X kg-1), but not Leu- or Met-enkephalin, microinjected into the third cerebral ventricle, significantly (P less than 0.01) decreased gastric acid secretion stimulated by pentagastrin. beta-Endorphin given intracerebroventricularly inhibited gastric acid secretion following 2-deoxy-D-glucose (P less than 0.01), but not after stimulation with histamine. Intravenous administration of beta-endorphin did not inhibit gastric acid secretion. beta-Endorphin decreased gastric acid secretion but not the concomitant release of gastrin stimulated by a 200-ml liquid meal containing 8% peptone. Pretreatment of the animals with the opioid antagonist, naloxone, prevented the gastric inhibitory effect of beta-endorphin. Furthermore, either ganglionic blockade with chlorisondamine or truncal vagotomy completely abolished the gastric inhibitory action of beta-endorphin. These findings indicate that beta-endorphin, but neither Leu- nor Met-enkephalin, acts within the CNS to inhibit gastric acid secretion in awake dogs. beta-Endorphin-induced inhibition of gastric acid secretion is mediated by an opiate-dependent pathway and by the autonomic (parasympathetic) nervous system.

Hippocampal and cortical opioid receptor binding: changes related to the hibernation state

In vitro opioid receptor binding in the dorsal hippocampal formation and parietal cortex was surveyed in ground squirrels (Citellus lateralis) in the contrasting physiological states of hibernation and euthermia (i.e. not hibernating). Computer-assisted autoradiographic analysis of coronal sections incubated with [3H]dihydromorphine (DMH; 4 nM) revealed statistically significant reductions in specific opioid binding associated with hibernation. In the dorsal hippocampal formation of hibernating animals, binding in the stratum radiatum of CA3, hilus of the dentate gyrus and molecular layer of the dentate gyrus exhibited decreases up to 34% compared to euthermic animals. The stratum radiatum of CA3 exhibited the smallest decrease overall. DHM binding in parietal cortex displayed significant hibernation-related reductions, although they were not uniformly observed across all laminae at the 3 different brain levels examined. These experiments present evidence of changes in brain opioid binding related to the mammalian state of hibernation. The results suggest that changes in opioid receptor binding during hibernation may contribute to the earlier reported apparent failure of morphine physical dependence to develop during hibernation.

Cardiac effects of thoracic epidural morphine caused by increased vagal activity in the dog

This study was carried out in order to investigate possible side-effects of thoracic epidural morphine on cardiac electrophysiology, haemodynamics and metabolism. In pentobarbital-anaesthetized dogs, intracardiac conduction times were determined by His bundle electrography, and refractoriness by programmed electrical stimulation; monophasic action potential recordings were obtained from the right ventricle by the suction electrode technique. Cardiac output, left ventricular and aortic blood pressures were measured, as well as plasma concentrations of morphine, free fatty acids, glycerol, glucose and lactate. Thoracic epidural morphine (0.12 mg X kg-1) reduced spontaneous heart rate, prolonged atrioventricular nodal conduction time and refractoriness, and reduced left ventricular dP/dt max. Bilateral vagotomy reversed these effects. Intra-atrial, His Purkinje and intraventricular conduction times, atrial and ventricular refractoriness and action potential duration, stroke volume and mean aortic blood pressure, as well as the metabolic variables, were not significantly influenced by thoracic epidural morphine with or without vagotomy. Peak plasma morphine levels of 12-25 ng X ml-1 were measured 10 min after morphine injection. In conclusion, this study demonstrates depressive side-effects of epidural morphine on cardiac function, mediated by an increased vagal activity.

Changes in body temperature and metabolic rate following microinjection of Met-enkephalinamide in the preoptic/anterior hypothalamus of rats

The effects of Met-enkephalinamide (MET-ENKamide) on brain temperature (Tb) and metabolic rate (MR) were assessed following direct administration into the preoptic/anterior hypothalamus (PO/AH) of freely moving rats. Bilateral microinjections of saline or MET-ENKamide (1-25 micrograms/microliter) were delivered through cannula guide tubes previously implanted in nine animals. Thiorphan, an enkephalinase inhibitor, was microinjected into the PO/AH of two of the animals. All injections were made remotely at an ambient temperature of 22 +/- 1 degree C in a volume of 1 microliter. Measurements of Tb (via a brain-dwelling thermistor) and MR were recorded continuously. The ability of naloxone to antagonize the effects of MET-ENKamide was investigated by fashioning a double-barreled injection cannula to fit within each guide tube; 1 microliter of saline or naloxone (1-10 micrograms) was delivered bilaterally into the PO/AH followed by 1 microliter of MET-ENKamide (25 micrograms) 5-10 min later. PO/AH administration of MET-ENKamide (1-25 micrograms) produced dose-dependent increases in Tb preceded by dose-dependent increases in MR, with a characteristic time course of approximately 30 min. Naloxone antagonized the rise in Tb and MR, either partially or completely, depending on dose. When administered alone, naloxone had no effect on Tb or MR. Microinjection of thiorphan (10 micrograms) into the PO/AH evoked increases in Tb and MR that were similar to those responses induced by MET-ENKamide. These results support a role for endogenous Met-enkephalin in the regulation of Tb in the rat.

Satiety, hunger and regional brain content of cholecystokinin/gastrin and met-enkephalin immunoreactivity in sheep

Cholecystokinin (CCK) and met-enkephalin (MEK) related peptides have been shown to alter feeding behavior subsequent to their injection into the peripheral circulation or directly into the brains of several species. To evaluate the potential role of endogenous brain pools of these peptides in feeding, groups of sheep were sacrificed either immediately following a meal (satiated) or after various intervals of food deprivation (hungry). Content of CCK-gastrin immunoreactivity in the anterior hypothalami of satiated sheep was elevated compared to 2, 4, or 24 hours of food deprivation. Content of MEK increased progressively with longer intervals of fasting (4 and 24 hours) in the amygdala and basomedial hypothalamus, whereas olfactory bulb content decreased with a similar time course. The results support a potential role for anterior hypothalamic CCK/gastrin in behaviors of satiety, whereas MEK neurons of limbic/rhinencephalic regions appear to form part of a separate circuit gradually activated by increasing hunger. Results are discussed in terms of potential target regions of the peptides, as well as the regional levels and feeding response of sheep as compared to available data from other species.

Topographical distribution of pro-opiomelanocortin-derived peptides (ACTH/beta-END/alpha-MSH) in the rat median eminence

The detailed distribution of adrenocorticotropin (ACTH), beta-endorphin (beta-END) and alpha-melanotropin (alpha-MSH) immunoreactivity was examined in the rat median eminence (ME) and pituitary stalk using light microscopic immunocytochemistry and radioimmunoassay (RIA). Nerve fibers and varicosities immunoreactive for ACTH/beta-END/alpha-MSH had identical distributions in the ME suggesting that they are part of the same arcuate proopiomelanocortin neuronal (POMC) system. The quantitative image analysis of POMC immunoreactive varicosities in the ME indicates no significant differences between the various rostro-caudal segments. In the main (preinfundibular) portion of the ME, a moderate density of immunoreactive elements was located in the lateral part of the internal zone and throughout the postinfundibular ME. Very few scattered varicosities were observed in the neurohemal (external) zone and in the pituitary stalk. By RIA, alpha-MSH is present in a substantially higher concentration than ACTH and beta-END throughout the ME. Knife cuts between the arcuate nucleus and ME indicate that proopiomelanocortin (POMC) fibers enter the ME in its whole rostro-caudal extent. Thus POMC neurons seem to provide innervation of structures in the internal zone but not in the neurohemal/external/zone where the portal capillary system is located. Moreover, the observation that the density of immunoreactive elements is substantially lower in the pituitary stalk than in the ME, suggests that the majority of immunoreactive fibers in the internal zone are not fibers of passage directed towards the neurohypophysis.

In vivo evidence for the selectivity of ICI 154129 for the delta-opioid receptor

The in vivo selectivity of the novel delta opioid-receptor antagonist N,N-bisallyl-Tyr-Gly-Gly-psi-(CH2S)-Phe-Leu-OH (ICI 154129) was examined in several opioid-selective models. Antagonism at the delta receptor was demonstrated in the striatal head-turn model in the rat. Intrapallidal injection of the relatively selective delta-receptor agonist D-Ala2,D-Leu5-enkephalin (0.5 micrograms) slowed the head-turn time and this effect was completely prevented by prior subcutaneous administration of ICI 154129 (30 mg/kg). The role of delta receptors in two classical test situations was studied using the mixed opioid agonist etorphine and the antagonists naloxone and ICI 154129. The drug ICI 154129 (30 mg/kg, s.c.) failed to prevent the antinociceptive effects and stimulation of locomotor activity produced by etorphine, whereas the relatively selective mu-opioid receptor antagonist, naloxone was effective in both test situations. The possible involvement of delta receptors in morphine-induced dependence was studied by monitoring the abstinence behaviour precipitated in rats given pellets of morphine by either ICI 154129 or naloxone. Naloxone (0.5 mg/kg, i.p.) precipitated a characteristic withdrawal syndrome in conscious rats and, at a much smaller dose (0.02 mg/kg, i.p.), induced shaking behaviour in pentobarbitone-anaesthetised rats. No withdrawal signs were observed in either model after injection of ICI 154129 (30 mg/kg, s.c.), suggesting that the delta receptors are not involved in dependence on morphine.

Site of action for beta-endorphin-induced changes in plasma luteinizing hormone and prolactin in the ovariectomized rat

A number of sites have been hypothesized as loci at which opioid substances act to alter the secretion of luteinizing hormone (LH) and prolactin (PRL) (1-8). The aim of the present study was to determine the site(s) at which the opioid peptide beta-endorphin (beta-END) acts to influence plasma LH and PRL levels in the ovariectomized (OVX) rat. beta-END, administered into the third ventricle of conscious OVX rats fitted with jugular catheters, significantly decreased plasma LH in doses greater than or equal to 50 ng and increased PRL levels at all doses administered (10, 50, 100 and 250 ng) in a dose dependent fashion. To identify possible central nervous system sites of action, 250 ng beta-END was unilaterally infused into various brain sites. Plasma LH was significantly decreased and plasma PRL significantly increased by infusions into the ventromedial hypothalamic area, the anterior hypothalamic area, and the preoptic-septal area. There was no significant effect of beta-END infusions into the lateral hypothalamic area, amygdala, midbrain central gray, or caudate nucleus. When hemipituitaries of OVX rats were incubated in vitro with beta-END (10(-7)M to 10(-5)M), there was no suppression of basal or LHRH-induced LH release, nor was there any alteration of basal PRL release. It is concluded that beta-END acts at a medial hypothalamic and/or preoptic-septal site and not the pituitary, to alter secretion of LH and PRL.

Radioimmunoassay of met-enkephalin in microdissected areas of paraformaldehyde-fixed rat brain

We studied the effect of various sample preparation procedures on rat brain met-enkephalin content, measured by radioimmunoassay. Whole brain met-enkephalin content of rats killed by decapitation followed by immediate tissue freezing was similar to that of rats killed by microwave irradiation and to those of rats anesthetized with pentobarbital or halothane before killing, whether previously perfused with paraformaldehyde or not. In contrast, a decrease (up to 80%) in met-enkephalin concentrations was observed when brain samples were frozen and thawed to mimic the procedure utilized in the "punch" technique for analysis of discrete brain nuclei. This decrease was totally prevented by paraformaldehyde perfusion of the brain prior to sacrifice. Brain perfusion did not alter the amount of immunoassayable met-enkephalin extracted from tissue or its profile after Sephadex chromatography. Paraformaldehyde perfusion results in better morphological tissue preservation and facilitates the "punch" dissecting technique. Paraformaldehyde perfusion may be the procedure of choice for the measurement of neuropeptides in specific brain nuclei dissected by the "punch" technique.

Hypothalamic regulation of the cardiovascular and respiratory systems: role of specific opiate receptors

Experiments were designed to evaluate the role of mu and delta opiate receptors in central cardiovascular control in the hypothalamic nucleus preopticus medialis of rats anaesthetized with pentobarbitone. The highly selective mu opiate receptor agonist D-Ala2-MePhe4-Gly5-ol-enkephalin was extremely potent in eliciting hypotension and bradypnoea; tachycardia was elicited by a low dose (0.064 nmol), but not by higher doses (0.64-6.4 nmol). Other selective mu receptor agonists (morphine sulphate, morphiceptin) caused tachycardia at lower doses (0.64, 6.4 nmol), hypotension and bradypnoea after the highest dose (64 nmol). The relatively selective delta receptor agonist D-Ala2-D-Leu5-enkephalin caused profound bradypnoea and hypotension at the high dose (64 nmol), tachycardia after the lowest dose (0.64 nmol), but bradycardia was found during the hypotension induced by the high dose (64 nmol). All of the opiate/opioid effects were reversed by naloxone (0.5 mg kg-1, i.v.). It is concluded that mu receptors may mediate the cardiovascular and respiratory effects of opiates and opioid peptides in the nucleus preopticus medialis of the rat.

Measurement of leucine enkephalin in caudate nucleus tissue with fast atom bombardment-collision activated dissociation-linked field scanning mass spectrometry

The endogenous amount of the opioid pentapeptide leucine enkephalin was measured in a canine caudate nucleus tissue extract using mass spectral analytical methods which retain absolute molecular specificity. Fast atom bombardment mass spectrometry generation of the protonated molecular ion of leucine enkephalin followed by collision activated dissociation produced amino acid sequence-determining ions. These amino acid sequence-determining ions were analyzed by a linked field (B/E) scan. One amino acid sequence-determining ion was selected to measure endogenous leucine enkephalin. This novel measurement mode offers optimal molecular specificity for quantification of an endogenous amount (451 pmol g-1 tissue) of leucine enkephalin in a biologic tissue extract of canine caudate nucleus.

Dynorphins and Leu-enkephalin in brain nuclei and pituitary of WKY and SHR rats

The distribution of dynorphin 1-13 (Dyn-1-13, Dyn-(1-8) and Leu5-enkephalin (LE) immunoreactivities (ir) were determined in discrete brain nuclei of normotensive (WKY) and hypertensive (SHR) rats. The concentration of ir-Dyn-(1-13) and ir-Dyn-(1-8) varied markedly among the various nuclei studies with a predominance of ir-Dyn-(1-13) over ir-Dyn-(1-8) in all the nuclei of both WKY and SHR rats. Ir-LE also showed large variations in different sites and no consistent relationships were found between the distribution of ir-Dyn-(1-8), Dyn-(1-13) and LE. SHR rats had lower levels of ir-Dyn-(1-13), Dyn-(1-8) and LE in the suprachiasmatic nucleus compared with WKY rats. In addition, SHR rats had lower levels of ir-Dyn-(1-8)- in the paraventricular and central amygdala, and higher ir-Dyn-(1-13) levels in the substantia nigra. The level of ir-Dyn-(1-13) in the neurointermediate lobe (NIL) of SHR rats was decreased substantially compared with that of WKY rats. The localization of these opioid peptides suggests that dynorphin-like peptides may serve a variety of hypothalamic and extrahypothalamic functions which might differ between SHR and WKY rats.

Uptake/internalization of Met-enkephalin by brain synaptosomes

In this manuscript, we provide evidence for the uptake of met-enkephalin by brain neurons. Tritiated met-enkephalin was accumulated by a crude synaptosomal fraction of rat brain, in the presence of peptidase inhibitors. Characterization of this process in striatum and mediobasal hypothalamus showed incubation time- and temperature-dependence and inhibition in part by several metabolic inhibitors. 3H-met-enkephalin uptake could be abolished in a dose-dependent manner by increasing concentrations of unlabelled met-enkephalin. Preincubation with naloxone resulted in up to 50% reduction of 3H-met-enkephalin uptake, suggesting a partial dependence on an opiate receptor interaction. 3H-met-enkephalin uptake was significantly reduced by freezing and thawing of the tissue preparation and completely abolished by addition of detergent or colchicine. The process showed dependence on substrate concentration, but was not saturable. Kinetic analysis of the 3H-met-enkephalin uptake revealed that the overall process best fit a transport model postulating the presence of a high-affinity, saturable uptake mechanism together with a second nonsaturable one. The uptake showed regional variation in brain with a distribution that closely paralleled those reported for met-enkephalin-like immunoreactivity and opiate receptor density. The precise significance of this 3H-met-enkephalin accumulation in brain remains to be determined. Whether this process represents 'reuptake' in the classical sense for termination of action, or internalization by some other process remains to be shown.

Neuropeptides in the median eminence: their sources and destinations

By radioimmunoassay and immunocytochemical techniques, 14 neuropeptides have been measured and localized in the rat median eminence. Neuropeptides with inhibitory or stimulatory effects on the anterior pituitary hormones as well as posterior pituitary hormones are present in the median eminence in the highest concentrations of the central nervous system. All these peptides (LH-RH, TRH, somatostatin, CRF, vasopressin, oxytocin) are of preoptic or hypothalamic origin and they are transported to the median eminence by loop-like fiber systems through the lateral retrochiasmatic area. Within the median eminence, the pericapillary space constitutes the main common pathway. Three major transport routes--axons, vessels, liquor spaces--are separated from each others by only basement membranes, which allow free communications downwards to the pituitary but also backwards to the central nervous system.

Endorphinergic and alpha-noradrenergic systems in the paraventricular nucleus: effects on eating behavior

Brain cannulated rats were injected with the opioid peptide beta-endorphin (beta-EP) directly into the hypothalamic paraventricular nucleus (PVN) where norepinephrine (NE) is most effective in stimulating eating behavior. Beta-Endorphin (1.0 nmole) reliably increased food intake in satiated animals, and this response was blocked by local administration of the selective opiate antagonist naloxone. The eating induced by beta-EP was positively correlated in magnitude with the NE response and, like NE, was antagonized by PVN injection of the alpha-noradrenergic blocker phentolamine. Naloxone had no effect on NE-induced eating, and the dopaminergic blocker fluphenazine failed to alter either beta-EP or NE eating. When injected simultaneously, at maximally effective doses, beta-EP and NE produced an eating response which was significantly larger than either of the responses elicited separately by beta-EP or NE and was essentially equal to the sum of these two responses. The evidence obtained in this study suggests that beta-EP and NE stimulate food ingestion through their action on PVN opiate and alpha-noradrenergic receptors, respectively, and that beta-EP's action is closely related to, and in part may be dependent upon, the PVN alpha-noradrenergic system for feeding control.

Regional distribution of alpha- and gamma-type endorphins in rat brain

The regional distribution of Met-enkephalin, beta-endorphin and alpha- and gamma-type endorphins in rat brain was investigated. To that end, brains were dissected into anatomically defined areas. Acetic acid tissue extracts were fractionated using an HPLC system suitable for separation of endorphins and peptide concentrations were subsequently measured by specific radioimmunoassay systems. The distribution of Met-enkephalin and beta-endorphin through the brain was fairly uneven and in accordance with results obtained by others. The peptides alpha-endorphin, gamma-endorphin, des-Tyr-alpha-endorphin (DT alpha E) and des-Tyr-gamma-endorphin (DT gamma E) were detectable in almost all brain areas. Their distribution, however, appeared to be uneven. Hypothalamus and septum showed the highest levels of alpha- and gamma-type endorphins. These regions also contained high amounts of beta-endorphin, underscoring a precursor function of this peptide in the formation of alpha- and gamma-type fragments. In general, levels of alpha-endorphin were higher than those of des-Try-alpha-endorphin, whereas the opposite was found for gamma- and des-Tyr-gamma-endorphin.

Effect of des-Tyr1-gamma-endorphin and des-Tyr1-alpha-endorphin on alpha-MPT-induced catecholamine disappearance in rat brain nuclei: a dose--response study

The effect of des-Tyr1-gamma-endorphin (beta-LPH62-77, DT gamma E) and des-Tyr1-alpha-endorphin (beta-LPH62-76, DT alpha E), administered intracerebroventricularly (icv) in doses of 0.01, 0.1, 1 and 10 micrograms, was studied on the alpha-methyl-p-tyrosine-(alpha-MPT) induced disappearance of catecholamines in a number of microdissected rat brain regions, which were selected on the basis of the neuroanatomy of the dopamine systems in the brain and of previous observations. A dose-dependent increase in the disappearance of dopamine in alpha-MPT-pretreated rats was observed following icv administration of DT gamma E in the nucleus interstitialis striae terminalis, the paraventricular nucleus, the anterior hypothalamic nucleus and the zona incerta. In these same brain regions a decrease in the alpha-MPT-induced disappearance of dopamine was found following the administration of DT alpha E, but only after doses of 0.01, 0.1 and 1 microgram. In none of these regions were effects observed after 10 micrograms of DT alpha E. No effects were seen on dopamine utilization in the nucleus accumbens, caudate nucleus and median eminence after any of the doses of DT gamma E or DT alpha E. The alpha-MPT-induced disappearance of noradrenaline was significantly enhanced in the anterior hypothalamic nucleus of rats treated with DT gamma E. It is concluded that DT gamma E and DT alpha E induce opposite changes in the utilization of dopamine selectively in brain regions which are predominantly innervated by neurons belonging to the intradiencephalic dopamine systems.

High-performance liquid chromatographic and field desorption mass spectrometric measurement of picomole amounts of endogenous neuropeptides in biologic tissue

A unique combination of chromatographic separation and mass spectrometric techniques has been developed for a novel method for measurement of picomole amounts of endogenous oligopeptides in biologic tissue. High-performance liquid chromatography is utilized for rapid high-resolution separation of peptides. A new buffer system using dilute triethylamine-formic acid is utilized. The buffer system possesses excellent UV transparent properties enabling femtomole sensitivity for measurement of standard solutions of somatostatin. Use of porous polystyrenedivinylbenzene copolymer and octadecylsilyl columns facilitate retention of a peptide fraction from biologic extracts. Advantage was taken of field desorption mass spectrometric methods to eliminate chemical derivatization of peptides and to produce protonated molecular ions which retain total molecular information of the peptide. Use of appropriate internal standards and selected ion monitoring methods enabled nanogram sensitivity and, more importantly, optimized structural specificity of the compound being quantified. Results are compatible with radioimmunoassay data. Data obtained with field desorption mass spectrometry provide, for the first time, measurement of intact, chemically underivatized oligopeptides extracted form biologic matrices and significantly, provide and analytic method to calibrate radioimmunoassay data. This novel combination of methods is being applied to measurements of peptide (leu-enkephalin, met-enkephalin, somatostatin, etc.) in canine brain regions and dental pulp tissue.

Absence of seizure activity following focal cerebral injection of enkephalins in a primate

Baboons (Papio papio) with photosensitive have been chronically prepared with guide cannulae and deep electrodes to study the effects of focal injections of opioids. In the hippocampus, amygdala and thalamus (centre median) 50--100 micrograms morphine, 20--100 micrograms Met-enkephalin or 2--10 micrograms FK 33,824 do not induce local or general electrographic or motor signs of epilepsy. The acute epileptogenic effect of morphine and enkephalins observed in rats is not a general phenomenon whereas the anticonvulsant action of opioids acting on mu-receptors is seen in rodents and primates.

The distribution of multiple opiate receptors in bovine brain

The distribution of mu and delta opiate receptors in bovine brain has been investigated using the selective radioligands [3H]morphine and D-[3H]Ala2, D-Leu5-enkephalin. Their distributions were found to vary independently through different brain areas with up to a 10-fold difference between the ratio of mu to delta binding sites for the substantia nigra and the dentate gyrus of the hippocampus.

The regional distribution of gamma 3-melanotropin-like peptides in bovine brain is correlated with adrenocorticotropin immunoreactivity but not with beta-endorphin

Immunoreactive (IR)-gamma 3-melanotropin (MSH), -adrenocorticotropin (ACTH) and -beta-endorphin in various areas of bovine brain were measured with their respective radioimmunoassays (RIA). The concentrations of IR-gamma 3-MSH were almost the same as those of IR-ACTH in most areas. Furthermore, in all brain regions, the concentrations of both peptides were lower than those of IR-beta-endorphin. The highest concentration of IR-gamma 3-MSH was found in hypothalamus, followed by thalamus, midbrain and striatum. Gel permeation chromatographic studies showed that the main gamma 3-MSH-like peptide in the hypothalamus, striatum and midbrain was a small form, whose molecular weight is about 4500. These brain gamma 3-MSH-like peptides were also found to be glycosylated.

Age-dependent changes in the beta-endorphin content of discrete rat brain nuclei

Concentrations of beta-endorphin were measured by radioimmunoassay in discrete brain nuclei of young (3 months) and old (24 months) rats. The beta-endorphin content of all major structures known to contain this peptide with the exception of the eminence, is reduced (50.3 +/- 2.8% of control) in old rats.

Regional distribution of gamma- and beta-endorphin-like peptides in the pituitary and brain of the rat

Sensitive and specific radioimmunoassays for gamma- and beta-endorphin-like peptides (gamma E and beta E) were used to examine the distribution and relationship of these peptides in the pituitary and in microdissected nuclear brain areas of the male rat. In the pituitary, the highest amounts of gamma E and beta E were found in the neurointermediate region of the gland. On a molar basis, gamma E-like immunoreactivity was found to exist as a relatively constant proportion of beta E-like peptides throughout the pituitary. In the brain, while beta E-like peptides were detected in many brain areas, gamma E-like peptides were detected in only a limited number of sites. In most of these areas, the molar ratio of gamma E to beta E-like peptides closely approximated that found in the pituitary. However, in the ventromedial nucleus of the hypothalamus and nucleus accumbens a higher proportion of gamma E to beta E was measured. These results suggest preferential formation of gamma E or related peptides in certain areas of the brain may occur.

Endogenous opiates: 1980

Vast amounts of research have been done that have attempted to delineate the pharmacological and physiological effects of the endogenous opiate peptides. A great deal of knowledge has also been accumulated in a limited time span concerning the types and locations of the opiate receptors and peptides, as well as their functions. In 1980, reports were made concerning the effects of these peptides on analgesia, on tolerance and dependence, on activity, on learning and memory, on schizophrenia and other types of emotional disturbances, and on physiological responses such as eating and drinking, cardiovascular responses, and sexual function. Additional understanding was also gained concerning their interactions with neurotransmitters, other neuropeptides, and hormones. These and other studies published only in 1980 are reviewed in this paper, which is the third of an annual series.